Prevalence of gastrointestinal, cardiovascular, autonomic, and allergic manifestations in hospitalized patients with Ehlers-Danlos syndrome: a case-control study
Abstract
OBJECTIVE
Previous observations suggest an association between Ehlers-Danlos syndrome (EDS) and gastrointestinal (GI), cardiovascular, immune, and autonomic nervous system dysfunction. We sought to determine whether a hospital diagnosis of EDS is associated with a higher prevalence of these manifestations vs hospitalized patients without EDS. We also evaluated hospital outcomes.
METHODS
6,021 cases and matched controls were acquired from the 2016 National Inpatient Sample. 2,007 EDS patients were identified via ICD-10 code. After bivariate analyses, multivariate logistic regression models were used to adjust for potential confounders.
RESULTS
GI conditions were found in 44% of EDS patients vs 18% of controls (odds ratio [OR]=3.57, confidence interval [CI]: 3.17-4.02, p < 0.0001), with irritable bowel syndrome, gastroparesis, and celiac disease strongly associated with EDS. Autonomic dysfunction, including postural orthostatic tachycardia syndrome (POTS), neurocardiogenic syncope, and orthostatic hypotension, was found in 20% of EDS patients vs 6% of controls (OR = 4.45, CI: 3.71-5.32, p < 0.0001). EDS patients were more likely to have food allergy (OR = 3.88, CI: 2.65-5.66, p < 0.0001) and cardiovascular complications, such as mitral valve disorders, aortic aneurysm, and dysrhythmias (OR = 6.16, CI: 4.60-8.23, p < 0.0001). These conditions remained highly-associated with EDS after considering confounders. EDS patients were 76% more likely to have longer-than-average…
How strong is the evidence?
Evidence Hub reads this as a case-control, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.